

CURRICULUM VITAE
Harold Dean Reeves, II, MD

Practice Address:

Metrolina Neurological Associates, PA
Metrolina Neurological Research Institute
1665 Herlong Ct, Suite B
Rock Hill, SC 29732

127 Professional Park Drive
Rock Hill, SC 29732
(803) 329-8635

Site Affiliations:

DJL Clinical Research, PLLC
431 N Wendover Rd
Charlotte, NC 28211

Education:

1996-1999	Neurology - Resident Medical College of Georgia
1995-1996	Internal Medicine - Intern Medical College of Georgia
1991-1995	Doctor of Medicine Bowman Gray School of Medicine
1986-1990	Bachelor of Science in Chemistry & Psychology Duke University

Professional Experience:

2017-Present	Metrolina Neurological Associates, PA Neurologist
1999-2017	AnMed Health Neurology Consultants Neurologist

Clinical Research:

Sub-Investigator – Adamas: A 3-Arm, Multicenter, Double-Blind, Placebo-Controlled, Randomized Study to Assess the Efficacy and Safety of ADS-5102 Amantadine Extended Release Capsules in Multiple Sclerosis Patients with Walking Impairment.

Sub-Investigator - AZTherapies: A phase III safety and efficacy study of AZT-OP1 in subjects with evidence of early Alzheimer's disease. ***High enrolling site**

CURRICULUM VITAE
Harold Dean Reeves, II, MD

Sub-Investigator – Adamas: A Multicenter, Open-Label Safety and Efficacy Study of ADS-5102 Amantadine Extended Release Capsules in Patients with Multiple Sclerosis and Walking Impairment. 2018

Sub-Investigator – Biohaven: A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention. 2019

Sub- Investigator – Novartis: Exploring the safety and tolerability of conversion from oral or injectable disease modifying therapies to dose-titrated Oral Siponimod in patients with advancing forms of relapsing multiple sclerosis: A 6-month open label, multicenter Phase IIIb study (EXCHANGE)

Sub- Investigator – Lilly: preventive Treatment of migraine: Outcomes for Patients in real-world Healthcare systems (TRIUMPH).

Sub- Investigator – Abbvie: A prospective observational study to evaluate the clinical outcomes and burden of disease of PD patients with motor fluctuations not adequately controlled by current PD medications. (PROSPECT)

Sub-Investigator – Novartis: A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study, Comparing the Efficacy and Safety of Remibrutinib Verses Teriflunomide in Participants with Relapsing Multiple Sclerosis, Followed by Extended Treatment with Open-Label Remibrutinib

My signature verifies the information in this document is accurate and updated appropriately.



Signature

2/15/23

Date